drugset / Trial / NCT01443403
A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine efficacy and safety of naldemedine for the treatment of opioid-induced constipation in adults with non-malignant chronic pain receiving opioid therapy for ≥ 3 months.
Timeline
- Start
- 2011-08-17
- Primary completion
- 2012-08-22
- Completion
- 2012-08-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Naldemedine | Other / unclassified | 0.1 mg | Oral |
| Subject | Naldemedine | Other / unclassified | 0.2 mg | Oral |
| Subject | Naldemedine | Other / unclassified | 0.4 mg | Oral |